Last updated: May 13, 2026
SCANDONEST PLAIN suppliers: who manufactures and distributes Scandonest Plain (articaine HCl + epinephrine) by country, channel, and regulatory status
Executive summary
Scandonest Plain is an articaine hydrochloride local anesthetic product (with epinephrine) marketed in multiple jurisdictions under “Scandonest Plain” and related brand/register names. Public-facing sourcing is channel-driven: (1) the marketing authorization holder (MAH) and its supply chain distributors for that country, and (2) pharmacy/wholesale wholesalers that import or distribute the MAH’s supply. To identify “suppliers” precisely, you must map each country’s MAH and listing in its drug register (or FDA/EMA equivalents) and then map the licensed wholesale distribution network serving tenders and hospitals.
No complete, jurisdiction-accurate supplier list can be produced from the information provided.
What is Scandonest Plain (active ingredients and typical packaging) and why does it affect supplier mapping?
Answer (what matters for suppliers): supplier identity changes by market because the MAH and packaging configuration are jurisdiction-specific, and “Scandonest Plain” may appear in registries under country-specific nomenclature, strengths, and pack sizes.
Drug substance and product form
- Active ingredient: articaine hydrochloride (local anesthetic)
- Co-ingredient: epinephrine (vasoconstrictor) in the “Plain” branded line
- Dosage form: injection for local anesthesia in dental and surgical procedures
- Market variable: cartridge size and needle accessories differ by country, so distribution SKUs differ
Why wholesalers list it differently than MAHs
- Tender systems often match by NDC-like identifiers, national product codes, or internal SKU
- Hospitals buy via regional distributors, not directly from MAHs
Who is the marketing authorization holder (MAH) for Scandonest Plain and how do they select distributors?
Answer: the MAH authorizes licensed wholesale distributors and importers in each jurisdiction; the MAH and their contracted distributor network are the de facto “suppliers” for that country’s channel.
Typical supplier structure by jurisdiction
- MAH (brand owner) in-market
- Licensed wholesale distributor/importer
- Pharmacy wholesale and hospital procurement contract holders
- Emergency stock providers used for dental and hospital supply chains
Evidence required to name specific companies
- National drug register listing (company/holder)
- Wholesale licensing register or procurement tender records
- If EU/UK: EMA EPAR does not replace national MAH listings for supply mapping
Which companies distribute Scandonest Plain in the EU/UK dental anesthesia channel?
Answer: distributors are market-specific; EU/UK supply is typically handled by a licensed wholesaler network tied to the MAH’s distribution authorization and national import arrangements.
How to map EU/UK distributors (channel logic used in practice)
- Identify the MAH for “Scandonest Plain” in the specific country.
- Cross-reference that MAH’s authorized distribution partners or listed supply contacts.
- Validate that distributor through country wholesale procurement listings (hospitals, dental chains, tender portals).
Common procurement patterns that affect “supplier” identification
- Hospital framework agreements (regional procurement bodies)
- Pharmacy wholesaler catalog availability (rebate/contracted supply)
- Importers who handle parallel trade where permitted
What suppliers exist for Scandonest Plain in hospital vs pharmacy vs online channels?
Answer: hospital supply relies on contracted tender distributors; pharmacy supply relies on pharmacy wholesalers; online “suppliers” can be gray-market importers unless tied to licensed distribution.
Hospital procurement suppliers
- Framework-tender wholesalers
- Direct distributor-to-hospital contracts
- Backup distributors for stockouts
Pharmacy wholesalers and distribution
- Retail pharmacy wholesalers supplying GP/dental clinics
- Bulk supply to dental clinic groups
Online marketplaces
- Many listings are re-shipped from licensed wholesalers or importers
- Some listings are parallel-import sellers
What patents and exclusivity matter for Scandonest Plain supplier competition?
Answer: “supplier competition” in generics is less about patent estate in the local anesthetic class than about regulatory listing and authorized manufacturing supply. For brand products, manufacturer and MAH distribution arrangements control early channel availability.
Practical implications for sourcing
- If an equivalent is authorized under different brand/label, suppliers may shift
- If substitution is allowed, hospitals and pharmacies may switch to equivalent articaine formulations
When does Scandonest Plain lose exclusivity and how does that change supplier lists?
Answer: supplier lists change only when authorization pathways enable additional branded or generic manufacturers to enter the local market and secure distribution contracts. Without a country-specific authorization and patent/exclusivity timeline, the exact entry timing cannot be stated.
What is the Orange Book status of Scandonest Plain and does that determine US suppliers?
Answer: Orange Book status only applies to US NDA/ANDA holders and would identify generic entry timelines and ANDA holders if listed. “Scandonest Plain” is often not directly mapped 1:1 to US Orange Book records because many dental anesthetic products in the US use different brand names and presentations.
How does Scandonest Plain compare with other articaine-epinephrine dental anesthetics for supplier substitutability?
Answer: supplier substitutability is driven by product equivalence (strengths, cartridge volume, epinephrine concentration, needle system compatibility) and local substitution rules, not by class alone.
Typical substitutable alternatives in practice
- Other articaine HCl with epinephrine cartridge products
- Lidocaine-epinephrine products where articaine is unavailable
- Local anesthetics by cartridge system and epinephrine concentration
What generic entry risks exist for Scandonest Plain that could expand suppliers?
Answer: generic entry risks depend on the exact US/EU/other regulatory status of each labeled presentation, manufacturing know-how, and whether equivalent active-drug/device packaging is accepted.
What manufacturing and IP barriers affect who can supply Scandonest Plain?
Answer: for injectable anesthetic cartridges, barriers tend to be:
- validated sterile manufacturing and container-closure controls
- cartridge and delivery system compatibility
- regulatory data ownership and listing requirements
- MAH contract and supply agreements controlling product allocation
Key Takeaways
- “Suppliers for Scandonest Plain” cannot be listed accurately without a country and without the MAH’s market authorization listing for the exact pack/strength.
- In practice, Scandonest Plain sourcing is defined by MAH distribution authorization and licensed wholesalers, with hospital supply determined by tender frameworks and pharmacy supply by contracted wholesalers.
- Any attempt to name specific supplier companies globally would be incomplete without jurisdiction-specific regulatory listing and procurement evidence.
FAQs
- How can I identify the MAH for Scandonest Plain in my country? (Use the national drug register listing for the exact strength and pack.)
- Which companies typically supply dental anesthetic cartridges to hospital group purchasing organizations? (Framework-tender licensed wholesalers tied to the MAH supply chain.)
- Do parallel imports change Scandonest Plain supplier options? (Yes, where permitted, they add importer/distributor brands but still rely on licensed distribution.)
- What product attributes most affect substitution of Scandonest Plain? (Articaine concentration, epinephrine concentration, cartridge volume, delivery system compatibility.)
- How do I assess whether an online seller can legally supply Scandonest Plain? (Confirm licensed wholesale/import status and traceability to the MAH supply chain or authorized distributor.)
References (APA)
- European Medicines Agency. (n.d.). European public assessment reports (EPAR). https://www.ema.europa.eu/
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA and Orange Book. https://www.accessdata.fda.gov/scripts/cder/daf/
- National drug registers. (n.d.). Country-specific medicine authorization and product listings. (Use the relevant national authority database for the target jurisdiction.)
